Lee Hartner

948 total citations
26 papers, 414 citations indexed

About

Lee Hartner is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Lee Hartner has authored 26 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Lee Hartner's work include Sarcoma Diagnosis and Treatment (13 papers), Vascular Tumors and Angiosarcomas (6 papers) and Head and Neck Cancer Studies (4 papers). Lee Hartner is often cited by papers focused on Sarcoma Diagnosis and Treatment (13 papers), Vascular Tumors and Angiosarcomas (6 papers) and Head and Neck Cancer Studies (4 papers). Lee Hartner collaborates with scholars based in United States, Poland and United Kingdom. Lee Hartner's co-authors include Arthur P. Staddon, William P. Levin, Warren Chow, Stephen M. Hahn, James D. Kolker, Brian C. Baumann, Abigail T. Berman, Kristy Weber, Eli Glatstein and Charles B. Simone and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The American Journal of Gastroenterology.

In The Last Decade

Lee Hartner

25 papers receiving 406 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lee Hartner United States 10 217 135 84 77 48 26 414
V. Barbounis Greece 15 115 0.5× 231 1.7× 102 1.2× 21 0.3× 71 1.5× 31 481
Michiaki Hirayama Japan 14 139 0.6× 169 1.3× 92 1.1× 18 0.2× 29 0.6× 56 575
Nicholas Campbell United States 11 264 1.2× 108 0.8× 127 1.5× 21 0.3× 31 0.6× 26 474
Michael Kellick United States 8 97 0.4× 102 0.8× 81 1.0× 24 0.3× 46 1.0× 12 402
Juan G. Posada Colombia 8 24 0.1× 83 0.6× 51 0.6× 28 0.4× 29 0.6× 22 244
Isabelle Genvresse Germany 12 105 0.5× 157 1.2× 107 1.3× 32 0.4× 104 2.2× 27 472
Y. Kenis Belgium 12 190 0.9× 238 1.8× 109 1.3× 21 0.3× 65 1.4× 59 503
Mustafa Dikilitaş Türkiye 12 210 1.0× 327 2.4× 107 1.3× 13 0.2× 56 1.2× 39 600
Jingjing Shang China 14 52 0.2× 196 1.5× 166 2.0× 61 0.8× 26 0.5× 63 486
Kelly K. Curtis United States 12 146 0.7× 130 1.0× 107 1.3× 19 0.2× 19 0.4× 25 375

Countries citing papers authored by Lee Hartner

Since Specialization
Citations

This map shows the geographic impact of Lee Hartner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lee Hartner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lee Hartner more than expected).

Fields of papers citing papers by Lee Hartner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lee Hartner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lee Hartner. The network helps show where Lee Hartner may publish in the future.

Co-authorship network of co-authors of Lee Hartner

This figure shows the co-authorship network connecting the top 25 collaborators of Lee Hartner. A scholar is included among the top collaborators of Lee Hartner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lee Hartner. Lee Hartner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berz, David, Olatunji B. Alese, David S. Hong, et al.. (2025). Tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) + FOLFIRI in 2L+ colorectal adenocarcinoma (CRC): Preliminary results from a phase 1 study.. Journal of Clinical Oncology. 43(4_suppl). 129–129. 1 indexed citations
2.
Loggers, Elizabeth T., Rashmi Chugh, Noah Federman, et al.. (2024). Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study. Cancer. 130(16). 2812–2821. 6 indexed citations
3.
Loggers, Elizabeth T., Rashmi Chugh, Lee Hartner, et al.. (2024). Monitoring ovarian function in oncology studies: Results and insights from the DeFi phase 3 study of nirogacestat in desmoid tumor.. Journal of Clinical Oncology. 42(16_suppl). 11520–11520. 1 indexed citations
4.
Tine, Brian Andrew Van, Jingqin Luo, Angela C. Hirbe, et al.. (2023). Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.. Journal of Clinical Oncology. 41(17_suppl). LBA11504–LBA11504. 8 indexed citations
5.
Luo, Xunda, et al.. (2022). Primary follicular lymphoma of the prostate presenting with elevated PSA and a PI-RADS 3 lesion on MRI: A case report. Urology Case Reports. 45. 102195–102195. 3 indexed citations
6.
Graillon, N., Oreste Iocca, Ryan M. Carey, et al.. (2021). What has the National Cancer Database taught us about oral cavity squamous cell carcinoma?. International Journal of Oral and Maxillofacial Surgery. 51(1). 10–17. 5 indexed citations
7.
Reddy, Vishruth K., Varsha Jain, Lee Hartner, et al.. (2021). Adult Pleomorphic Rhabdomyosarcomas: Assessing Outcomes Associated with Radiotherapy and Chemotherapy Use in the National Cancer Database. Sarcoma. 2021. 1–11. 1 indexed citations
8.
Baumann, Brian C., Karen De Amorim Bernstein, Thomas F. DeLaney, et al.. (2020). Multi‐institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity. Journal of Surgical Oncology. 122(5). 877–883. 30 indexed citations
9.
10.
Chow, Warren, Paul Frankel, Dejka M. Araujo, et al.. (2019). Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma. Cancer. 126(1). 105–111. 49 indexed citations
11.
Mowery, Yvonne M., Karla V. Ballman, Richard F. Riedel, et al.. (2018). SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.. Journal of Clinical Oncology. 36(15_suppl). TPS11588–TPS11588. 10 indexed citations
12.
Hartner, Lee. (2017). Chemotherapy for Oral Cancer. Dental Clinics of North America. 62(1). 87–97. 98 indexed citations
13.
Workman, Alan D., Douglas Farquhar, Robert M. Brody, et al.. (2017). Leiomyosarcoma of the head and neck: A 17‐year single institution experience and review of the National Cancer Data Base. Head & Neck. 40(4). 756–762. 13 indexed citations
14.
Baumann, Brian C., S. Nagda, James D. Kolker, et al.. (2016). Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection. Journal of Surgical Oncology. 114(1). 65–69. 57 indexed citations
15.
Hartner, Lee, et al.. (2014). Vitamin D deficiency in the oncology setting. The Journal of Community and Supportive Oncology. 12(1). 13–19. 6 indexed citations
16.
Patel, Mihir R., et al.. (2014). Primary granulocytic sarcoma of larynx. Head & Neck. 37(3). E38–E44. 5 indexed citations
17.
Winer, Eric S., Howard Safran, Bogusława Karaszewska, et al.. (2014). Eltrombopag with gemcitabine‐based chemotherapy in patients with advanced solid tumors: a randomized phase I study. Cancer Medicine. 4(1). 16–26. 39 indexed citations
18.
19.
Ogilvie, Christian M., Eileen A. Crawford, Joseph J. King, et al.. (2010). Treatment of Adult Rhabdomyosarcoma. American Journal of Clinical Oncology. 33(2). 128–131. 37 indexed citations
20.
Staddon, Arthur P., Eileen A. Crawford, Lee Hartner, Richard D. Lackman, & Christian M. Ogilvie. (2008). Treatment of metastatic sarcomatoid carcinoma with doxorubicin and ifosfamide. Journal of Clinical Oncology. 26(15_suppl). 21518–21518. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by V. Barbounis Breakdown of academic impact, for papers by Michiaki Hirayama Breakdown of academic impact, for papers by Nicholas Campbell Breakdown of academic impact, for papers by Michael Kellick Breakdown of academic impact, for papers by Juan G. Posada Breakdown of academic impact, for papers by Isabelle Genvresse Breakdown of academic impact, for papers by Y. Kenis Breakdown of academic impact, for papers by Mustafa Dikilitaş Breakdown of academic impact, for papers by Jingjing Shang Breakdown of academic impact, for papers by Kelly K. Curtis
Rankless by CCL
2026